HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial

Background. The iPrEx study demonstrated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects against HIV acquisition in men who have sex with men and transgender women. Selection for drug resistance could offset PrEP benefits. Me...

Descripción completa

Detalles Bibliográficos
Autores principales: Liegler, Teri, Abdel-Mohsen, Mohamed, Bentley, L. Gordon, Atchison, Robert, Schmidt, Timothy, Javier, Jacqueline, Mehrotra, Megha, Eden, Christopher, Glidden, David V., McMahan, Vanessa, Anderson, Peter L., Li, Peilin, Wong, Joseph K., Buchbinder, Susan, Guanira, Juan V., Grant, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176446/
https://www.ncbi.nlm.nih.gov/pubmed/24740633
http://dx.doi.org/10.1093/infdis/jiu233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176446/
https://www.ncbi.nlm.nih.gov/pubmed/24740633
http://dx.doi.org/10.1093/infdis/jiu233

Ejemplares similares